Skip to content

Clinical efficacy evaluation and mechanism study of Wenshenxiaoyao Granules in treating renal deficiency liver-depression perimenopausal dry eyes

Clinical efficacy evaluation and mechanism study of Wenshenxiaoyao Granules in treating renal deficiency liver-depression perimenopausal dry eyes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000661
Enrollment
Unknown
Registered
2024-11-06
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perimenopausal dry eyes

Interventions

Sponsors

Eye Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Patients with dry eye. 2. Perimenopausal(Ages 40-55) women who meet the syndrome of kidney deficiency and liver stagnation. 3. Patients who are currently using artificial tears or anti-inflammatory eye drops should wait for one week after discontinuing the medication before being included. 4. Participants have signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with scleral scarring Sjogren's syndrome or severe meibomian glanditis. 2. Patients with glaucoma who require topical hypotensive medication to control intraocular pressure. 3. Perimenopausal women with emotional disorders or severe cardiovascular cerebrovascular or liver and kidney diseases with liver and kidney function exceeding normal values by 2 times or more. 4. Patients who have used sex hormones within the past 3 months. 5. Patients who are currently participating in other drug clinical trials or who are taking similar Chinese herbal medicines and other treatments. 6. Patients who do not wish to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
Tear film rupture time;Ocular symptom score;

Secondary

MeasureTime frame
General Symptom Score;Tear secretion function;Meibomian gland deletion score;Lipid layer score;Conjunctival imprinted cell count and inflammatory factor expression levels;Sex hormone and anti-Miller hormone levels;Conjunctival congestion score;Lacrimal river height;Dry eye related quality of life score;Corneal epithelial status;

Countries

China

Contacts

Public ContactLianrong Yin

Eye Hospital China Academy of Chinese Medical Sciences

yinlrye@126.com+86 13810710448

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026